Mark Oremus, Mark Hanson, Richard Whitlock, Ed Young, Alok Gupta, Arianna Dal Cin, Carolyn Archer, Parminder Raina
{"title":"The uses of heparin to treat burn injury.","authors":"Mark Oremus, Mark Hanson, Richard Whitlock, Ed Young, Alok Gupta, Arianna Dal Cin, Carolyn Archer, Parminder Raina","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>To assess the evidence for using heparin in the treatment of burn injury or the complications of burn injury in adults and children.</p><p><strong>Data sources: </strong>The following databases were searched: MEDLINE (1966-current), EMBASE (1980-current), Cumulative Index to Nursing & Allied Health (CINAHL) (1982-current), The Cochrane Central Database of Controlled Trials (1995-current), Web of Science (1976-current), and BIOSIS (1976-current). Additional data sources included the U.S. and European Patent Offices, technical experts, the partner organization, and reference lists.</p><p><strong>Review methods: </strong>Studies identified from the data sources went through two levels of title and abstract screening. Passing studies advanced to full text screening. Studies that met the full text screening criteria were abstracted. Criteria for abstraction included publication in any language, human patients of any age, and burns of any type, grade, or total body surface area. All formulations of heparin, and all application methods (e.g., topical, subcutaneous), were eligible for inclusion in the report. Abstracted studies required a comparison group. Outcomes of interest included mortality, pain, length of stay in hospital, thrombosis and emboli, psychiatric adjustment, and adverse effects (e.g., bleeding).</p><p><strong>Results: </strong>Nineteen articles from 18 unique studies were abstracted and included in this report. In these articles, there were multiple uses of heparin to treat burns (e.g., wound healing, inhalation injury, sepsis, pain). However, the overall quality of the articles was weak. Examples of weakness included unclear or inappropriate treatment allocation, no blinding, no control of confounding, poorly defined burn characteristics (e.g., thickness), unclear duration of treatment, incomplete description of heparin treatment, and use of inadequately described or invalid outcome measures. Overall, the evidence from these weak articles was insufficient to determine whether the effectiveness of heparin to treat burn injury was different from the effectiveness of other treatments, or whether treatment effectiveness varied according to (a) the method of applying heparin to (b) burn etiology. Four studies mentioned contraindications to using heparin to treat burns. These contraindications were bleeding diathesis, bleeding history, active bleeding or associated trauma with potential bleeding, active intestinal ulcer, thrombocytopenia, liver disease, renal disorders, or allergy to heparin.</p><p><strong>Conclusions: </strong>There is no strong evidence in the 19 abstracted articles to suggest that heparin should be used in the treatment of burn injury on account of its non-anticoagulant properties.</p>","PeriodicalId":72991,"journal":{"name":"Evidence report/technology assessment","volume":" 148","pages":"1-58"},"PeriodicalIF":0.0000,"publicationDate":"2006-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4781157/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Evidence report/technology assessment","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: To assess the evidence for using heparin in the treatment of burn injury or the complications of burn injury in adults and children.
Data sources: The following databases were searched: MEDLINE (1966-current), EMBASE (1980-current), Cumulative Index to Nursing & Allied Health (CINAHL) (1982-current), The Cochrane Central Database of Controlled Trials (1995-current), Web of Science (1976-current), and BIOSIS (1976-current). Additional data sources included the U.S. and European Patent Offices, technical experts, the partner organization, and reference lists.
Review methods: Studies identified from the data sources went through two levels of title and abstract screening. Passing studies advanced to full text screening. Studies that met the full text screening criteria were abstracted. Criteria for abstraction included publication in any language, human patients of any age, and burns of any type, grade, or total body surface area. All formulations of heparin, and all application methods (e.g., topical, subcutaneous), were eligible for inclusion in the report. Abstracted studies required a comparison group. Outcomes of interest included mortality, pain, length of stay in hospital, thrombosis and emboli, psychiatric adjustment, and adverse effects (e.g., bleeding).
Results: Nineteen articles from 18 unique studies were abstracted and included in this report. In these articles, there were multiple uses of heparin to treat burns (e.g., wound healing, inhalation injury, sepsis, pain). However, the overall quality of the articles was weak. Examples of weakness included unclear or inappropriate treatment allocation, no blinding, no control of confounding, poorly defined burn characteristics (e.g., thickness), unclear duration of treatment, incomplete description of heparin treatment, and use of inadequately described or invalid outcome measures. Overall, the evidence from these weak articles was insufficient to determine whether the effectiveness of heparin to treat burn injury was different from the effectiveness of other treatments, or whether treatment effectiveness varied according to (a) the method of applying heparin to (b) burn etiology. Four studies mentioned contraindications to using heparin to treat burns. These contraindications were bleeding diathesis, bleeding history, active bleeding or associated trauma with potential bleeding, active intestinal ulcer, thrombocytopenia, liver disease, renal disorders, or allergy to heparin.
Conclusions: There is no strong evidence in the 19 abstracted articles to suggest that heparin should be used in the treatment of burn injury on account of its non-anticoagulant properties.
目的:评价肝素在成人和儿童烧伤及烧伤并发症治疗中的应用证据。资料来源:检索了以下数据库:MEDLINE(1966年至今)、EMBASE(1980年至今)、护理与联合健康累积指数(CINAHL)(1982年至今)、Cochrane中央对照试验数据库(1995年至今)、Web of Science(1976年至今)和BIOSIS(1976年至今)。其他数据来源包括美国和欧洲专利局、技术专家、合作伙伴组织和参考列表。回顾方法:从数据源中确定的研究经过标题和摘要筛选两个层次。通过的研究进展到全文筛选。符合全文筛选标准的研究被摘要。摘要标准包括以任何语言发表、任何年龄的人类患者、任何类型、等级或全身面积的烧伤。所有肝素制剂和所有应用方法(如外用、皮下)均符合纳入报告的条件。摘要研究需要一个比较组。关注的结局包括死亡率、疼痛、住院时间、血栓形成和栓塞、精神调整和不良反应(如出血)。结果:从18项独特的研究中摘录了19篇文章并纳入本报告。在这些文章中,有肝素治疗烧伤的多种用途(例如,伤口愈合,吸入性损伤,败血症,疼痛)。然而,文章的整体质量较弱。弱点的例子包括不清楚或不适当的治疗分配,没有盲法,没有混杂控制,烧伤特征定义不清(如厚度),治疗持续时间不明确,肝素治疗描述不完整,使用描述不充分或无效的结果测量。总的来说,来自这些薄弱文章的证据不足以确定肝素治疗烧伤的有效性是否与其他治疗的有效性不同,或者治疗效果是否根据(a)应用肝素的方法(b)烧伤病因而变化。四项研究提到了使用肝素治疗烧伤的禁忌症。这些禁忌症是出血体质、出血史、活动性出血或伴有潜在出血的相关创伤、活动性肠溃疡、血小板减少症、肝脏疾病、肾脏疾病或对肝素过敏。结论:19篇摘要文章中没有强有力的证据表明肝素因其非抗凝血性能而应用于烧伤治疗。